TR European Growth Trust
Rated Fund 2017-19. Buys undervalued smaller companies
TR European Growth was named Best European Trust in Money Observer’s 2017 investment trust awards and Best Large Trust in 2018. A 13% collapse in its discount to net assets over the past year masks the fact that it only marginally underperformed its benchmark over the past year. It remains a solid longer-term performer.
Ollie Beckett, its manager since 2011, seeks to achieve the trust’s growth objective by investing primarily in small and medium-sized companies. With a diversified portfolio of 140 holdings, he is prepared to venture well down the size spectrum in search of companies with exceptional growth potential.
Beckett looks for undervalued companies that can either deliver substantial growth or where there is potential for improvements in profitability through self-help. This focus means that he does not try to allocate investments on a country or sector basis. However, the manager stresses that he does pay attention to the make-up of the portfolio to avoid concentration risk.
His emphasis is on seeking to identify situations where he believes the market perception is wrong and the company is undervalued. He and the rest of Janus Henderson’s European equities team are keen to generate their own investment ideas and spend a lot of time meeting companies’ management teams. In that way they get to know and understand the drivers of industries and stocks and can identify companies with strong competitive positions in niche markets.
Beckett also believes that a selling discipline is vital in small company investing and he does not hesitate to take profits, with individual holdings usually representing no more than just over 2% of net assets.
Narrative and ratings content all as of 01 January 2019.See all Money Observer rated funds
|Van Lanschot Kempen NV||2.34 %|
|DFDS A/S||2.32 %|
|Gaztransport et technigaz SA||2.08 %|
|Soitec SA||1.80 %|
|TKH Group NV||1.76 %|
|Banca Farmafactoring SpA||1.72 %|
|OC Oerlikon Corp AG, Pfaffikon||1.64 %|
|Dermapharm Holding SE Bearer Shares||1.61 %|
|Koninklijke Boskalis Westminster NV||1.54 %|
|Europe - ex Euro||26.26 %|
|Consumer Cyclical||16.07 %|
|Financial Services||13.68 %|
|Basic materials||11.41 %|
Rory Stokes is a Fund Manager of European equities at Janus Henderson Investors, a position he has held since 2015. Rory joined Henderson in 2013 as a European equity analyst. He worked for Liberum Capital Limited in small- and mid-cap equity sales from 2007 and prior to that held several roles at Credit Suisse. He began his career at HOLT Value Associates as a research analyst in 2001. Rory graduated with a degree in philosophy, politics, and economics from Oxford University. He holds the Chartered Financial Analyst designation and is FCA registered.
Ollie Beckett is a Portfolio Manager of European equities at Janus Henderson Investors responsible for the European Focus and International Small Cap Equity strategies. Ollie first joined Henderson as an assistant portfolio manager for European equities upon the firm’s merger with AMP Asset Management in 1998 and was named fund manager in 1999. He moved to the Global Technology Team in 2000. He left Henderson in 2003 to pursue other interests before returning to his current role with the firm in 2005. Ollie received a BA degree in economics and government from the University of Manchester.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.